In conclusion, deoxypyrimidine supplementation for Tk2 deficiency is the first effective and safe in vivo treatment option that may be readily translated to patient affected by Tk2 mutations. This evidence concerns the gene TK2 and hyperinsulinemic hypoglycemia, familial, 4.